ADMA Biologics Inc

$20.23
(as of Mar 28, 3:57 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for ADMA Biologics Inc

Stock Price
$20.23
Ticker Symbol
ADMA
Exchange
NASDAQ

Industry Information for ADMA Biologics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for ADMA Biologics Inc

Country
USA
Full Time Employees
685

ADMA Biologics, Inc., a commercial biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics. In addition, the company operates source plasma collection facilities, including collections of source plasma, procurement of raw materials and packaging materials, and the testing of finished drug products. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Fundamentals for ADMA Biologics Inc

Market Capitalization
$4,814,080,000
EBITDA
$147,028,000
Dividends per Share
P/E Ratio
25.01
Forward P/E Ratio
28.99
Earnings per Share
$0.81
Earnings per Share Estimate Next Year
Profit Margin
46.35%
Shares Outstanding
237,615,008
Percent Owned by Insiders
2.61%
Percent Owned by Institutions
88.43%
52-Week High
52-Week Low

Technical Indicators for ADMA Biologics Inc

50-Day Moving Average
200-Day Moving Average
RSI
64.25
0.96

Analyst Ratings for ADMA Biologics Inc

Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About ADMA Biologics Inc

Mar 19, 2025, 9:02 PM EST
We recently published a list of Pulse of the Market: Wednesday’s 10 Top Performers. See more.
Mar 4, 2025, 1:50 PM EST
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ADMA Biologics, Inc. See more.
Mar 3, 2025, 4:05 PM EST
FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase See more.
Feb 28, 2025, 7:00 AM EST
RAMSEY, N.J. and BOCA RATON, Fla., Feb. See more.